ghk-cu acetat topical Cream Compounded GHK-Cu Topical Cream —

"As we look to build an impactful portfolio of medicines to address patient needs, our data presented at ADA 2025 demonstrates not only how we are already delivering for a wide range of these needs with semaglutide, but that we are continuing to invest in innovation to support people living with serious chronic disease." The presentation of the CagriSema REDEFINE 1 and 2 trials are the first ever Phase 3 data presented on a GLP-1 and amylin receptor agonist combination, offering insights into the potential of this investigational medicine

By targeting healing where it actually happens, at the cellular level, BPC-157 promotes faster recovery and improved tissue function

Cagrilintide + Semaglutide is a fixed dose combination of a long acting amylin analogue and a GLP 1 receptor agonist, studied as CagriSema in adults with overweight or obesity, with and without type 2 diabetes

Mycobacterium marinum engineered to fluoresce when encountering a Pi concentration of 1500 lipid species and allowing Mtb to overcome Pi limitation

Impact of Ozempic (Semaglutide) Semaglutide is a medication that belongs to a class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1 RAs)